• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mitochondrial dysfunction as a crucial mediator of ADT-induced cardiovascular risk.

作者信息

Lin Yu-Hsiang, Lin Kuo-Jen, Juang Horng-Heng

机构信息

Department of Urology, Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan.

School of Medicine, Chang Gung University, Taoyuan, Taiwan.

出版信息

Nat Rev Urol. 2025 Jun 5. doi: 10.1038/s41585-025-01050-6.

DOI:10.1038/s41585-025-01050-6
PMID:40473872
Abstract
摘要

相似文献

1
Mitochondrial dysfunction as a crucial mediator of ADT-induced cardiovascular risk.线粒体功能障碍是雄激素剥夺治疗诱导心血管风险的关键介质。
Nat Rev Urol. 2025 Jun 5. doi: 10.1038/s41585-025-01050-6.
2
Reply to 'Mitochondrial dysfunction as a crucial mediator of ADT-induced cardiovascular risk'.对“线粒体功能障碍作为雄激素剥夺治疗诱导心血管风险的关键介质”的回复
Nat Rev Urol. 2025 Jun 5. doi: 10.1038/s41585-025-01049-z.
3
ADT-OH exhibits anti-metastatic activity on triple-negative breast cancer by combinatorial targeting of autophagy and mitochondrial fission.ADT-OH 通过组合靶向自噬和线粒体分裂对三阴性乳腺癌表现出抗转移活性。
Cell Death Dis. 2024 Jun 28;15(6):463. doi: 10.1038/s41419-024-06829-w.
4
Significance of androgen-deprivation therapy for intermediate- and high-risk prostate cancer treated with high-dose radiotherapy: A literature review.高剂量放疗治疗中高危前列腺癌行去势治疗的意义：文献复习。
Int J Urol. 2024 Oct;31(10):1068-1079. doi: 10.1111/iju.15535. Epub 2024 Jul 17.
5
Pharmacologic androgen deprivation and cardiovascular disease risk factors: a systematic review.药物去雄激素治疗与心血管疾病危险因素：系统评价。
Eur J Clin Invest. 2015 May;45(5):475-84. doi: 10.1111/eci.12431.
6
Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada.恩杂鲁胺联合雄激素剥夺疗法（ADT）与单纯ADT治疗加拿大高危生化复发非转移性去势敏感性前列腺癌的成本效益
J Med Econ. 2025 Dec;28(1):766-777. doi: 10.1080/13696998.2025.2503660. Epub 2025 May 23.
7
Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis.前列腺癌患者雄激素剥夺治疗相关的心血管事件：一项系统评价和荟萃分析。
World J Urol. 2015 Sep;33(9):1281-9. doi: 10.1007/s00345-014-1439-6. Epub 2014 Nov 12.
8
Preferences between three options for androgen deprivation therapy: a focus group study.
BJU Int. 2025 Jul 30. doi: 10.1111/bju.16863.
9
Do Older Patients With Metastatic Hormone-Sensitive Prostate Cancer Benefit From Triplet or Doublet Therapy? A Network Meta-Analysis.老年转移性激素敏感性前列腺癌患者从三联或双联疗法中获益吗？一项网状Meta分析。
Clin Genitourin Cancer. 2025 May 30:102380. doi: 10.1016/j.clgc.2025.102380.
10
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.

引用本文的文献

1
Mitochondrial dysfunction as the missing mechanistic link between hand grip strength and CKD progression.线粒体功能障碍是握力与慢性肾脏病进展之间缺失的机制联系。
Int Urol Nephrol. 2025 Jul 15. doi: 10.1007/s11255-025-04665-1.
2
Reply to 'Mitochondrial dysfunction as a crucial mediator of ADT-induced cardiovascular risk'.对“线粒体功能障碍作为雄激素剥夺治疗诱导心血管风险的关键介质”的回复
Nat Rev Urol. 2025 Jun 5. doi: 10.1038/s41585-025-01049-z.

本文引用的文献

1
Reply to 'Mitochondrial dysfunction as a crucial mediator of ADT-induced cardiovascular risk'.对“线粒体功能障碍作为雄激素剥夺治疗诱导心血管风险的关键介质”的回复
Nat Rev Urol. 2025 Jun 5. doi: 10.1038/s41585-025-01049-z.
2
The critical role of mitochondrial dysfunction in ADT-induced neurotoxicity.线粒体功能障碍在雄激素剥夺治疗诱导的神经毒性中的关键作用。
Prostate Cancer Prostatic Dis. 2025 Mar 3. doi: 10.1038/s41391-025-00958-9.
3
Assessing the effects of prostate cancer therapies on cardiovascular health.评估前列腺癌治疗对心血管健康的影响。
Nat Rev Urol. 2025 Feb 26. doi: 10.1038/s41585-025-01002-0.
4
Mitochondrial dysfunction: mechanisms and advances in therapy.线粒体功能障碍：机制与治疗进展。
Signal Transduct Target Ther. 2024 May 15;9(1):124. doi: 10.1038/s41392-024-01839-8.
5
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis.前列腺癌雄激素剥夺治疗与神经认知障碍：一项系统评价与荟萃分析
Prostate Cancer Prostatic Dis. 2024 Sep;27(3):507-519. doi: 10.1038/s41391-023-00785-w. Epub 2024 Jan 2.
6
Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.代谢综合征及其药物治疗与去势抵抗性前列腺癌的发生时间相关。
Prostate Cancer Prostatic Dis. 2022 Feb;25(2):320-326. doi: 10.1038/s41391-022-00494-w. Epub 2022 Jan 24.
7
Mitochondrial Dysfunction and Heart Disease: Critical Appraisal of an Overlooked Association.线粒体功能障碍与心脏病：被忽视关联的批判性评价。
Int J Mol Sci. 2021 Jan 9;22(2):614. doi: 10.3390/ijms22020614.
8
Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications.心血管疾病中的线粒体功能障碍：转化研究的现状/临床及治疗意义
Med Res Rev. 2021 Jan;41(1):275-313. doi: 10.1002/med.21732. Epub 2020 Sep 21.
9
Low testosterone levels are related to oxidative stress, mitochondrial dysfunction and altered subclinical atherosclerotic markers in type 2 diabetic male patients.低睾酮水平与2型糖尿病男性患者的氧化应激、线粒体功能障碍及亚临床动脉粥样硬化标志物改变有关。
Free Radic Biol Med. 2017 Jul;108:155-162. doi: 10.1016/j.freeradbiomed.2017.03.029. Epub 2017 Mar 27.
10
Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?线粒体：化疗诱导的骨骼肌毒性和消瘦的意外靶点？
Cancer Chemother Pharmacol. 2016 Oct;78(4):673-83. doi: 10.1007/s00280-016-3045-3. Epub 2016 May 11.